Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aim: To present our experience with sentinel lymph node biopsy (SLNB) performed in patients with multicentric breast cancer. Methods: Between May 2001 and May 2004, 42 patients with multicentric breast cancer and a clinically negative axilla underwent lymphatic mapping either by a single subareolar (n=25) or a double peritumoral/subdermal injection (n=17) of 99Tc-HSA nanocolloids. The sentinel lymph node (SLN) was evaluated by intraoperative frozen section and axillary dissection was performed only in case of positive SLN. Results: Mean age was 49 years (range 25-78). Mean number of SLNs identified by lymphoscintigraphy was 1.36 (range 1-5) and mean number of SLNs removed at surgery was 1.55 (range 1-5), with an identification rate of 100%. The mean number of hot spots identified by lymphoscintigraphy was similar in patients who underwent single or double injections (1.36 and 1.35, respectively). In 21 of 42 patients the SLN was positive, and in seven of these 21 patients the SLN was the only positive node. After a median follow-up of 24 months no overt axillary metastases occurred in patients with negative SLN. Conclusions: The number of SLNs is not dependent on the number and site of injections. SLNB is our standard procedure for nodal staging in patients with multicentric breast cancer and a clinically negative axilla.

Original languageEnglish
Pages (from-to)507-510
Number of pages4
JournalEuropean Journal of Surgical Oncology
Volume32
Issue number5
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Lymphoscintigraphy
Axilla
Injections
Frozen Sections
Dissection
Sentinel Lymph Node
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Multicentric
  • Sentinel node

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

@article{b3123dab1fa34150bcc2c1d0675a130f,
title = "Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology",
abstract = "Aim: To present our experience with sentinel lymph node biopsy (SLNB) performed in patients with multicentric breast cancer. Methods: Between May 2001 and May 2004, 42 patients with multicentric breast cancer and a clinically negative axilla underwent lymphatic mapping either by a single subareolar (n=25) or a double peritumoral/subdermal injection (n=17) of 99Tc-HSA nanocolloids. The sentinel lymph node (SLN) was evaluated by intraoperative frozen section and axillary dissection was performed only in case of positive SLN. Results: Mean age was 49 years (range 25-78). Mean number of SLNs identified by lymphoscintigraphy was 1.36 (range 1-5) and mean number of SLNs removed at surgery was 1.55 (range 1-5), with an identification rate of 100{\%}. The mean number of hot spots identified by lymphoscintigraphy was similar in patients who underwent single or double injections (1.36 and 1.35, respectively). In 21 of 42 patients the SLN was positive, and in seven of these 21 patients the SLN was the only positive node. After a median follow-up of 24 months no overt axillary metastases occurred in patients with negative SLN. Conclusions: The number of SLNs is not dependent on the number and site of injections. SLNB is our standard procedure for nodal staging in patients with multicentric breast cancer and a clinically negative axilla.",
keywords = "Breast cancer, Multicentric, Sentinel node",
author = "O. Gentilini and G. Trifir{\`o} and J. Soteldo and A. Luini and M. Intra and V. Galimberti and P. Veronesi and L. Silva and S. Gandini and G. Paganelli and U. Veronesi",
year = "2006",
month = "6",
doi = "10.1016/j.ejso.2006.02.018",
language = "English",
volume = "32",
pages = "507--510",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology

AU - Gentilini, O.

AU - Trifirò, G.

AU - Soteldo, J.

AU - Luini, A.

AU - Intra, M.

AU - Galimberti, V.

AU - Veronesi, P.

AU - Silva, L.

AU - Gandini, S.

AU - Paganelli, G.

AU - Veronesi, U.

PY - 2006/6

Y1 - 2006/6

N2 - Aim: To present our experience with sentinel lymph node biopsy (SLNB) performed in patients with multicentric breast cancer. Methods: Between May 2001 and May 2004, 42 patients with multicentric breast cancer and a clinically negative axilla underwent lymphatic mapping either by a single subareolar (n=25) or a double peritumoral/subdermal injection (n=17) of 99Tc-HSA nanocolloids. The sentinel lymph node (SLN) was evaluated by intraoperative frozen section and axillary dissection was performed only in case of positive SLN. Results: Mean age was 49 years (range 25-78). Mean number of SLNs identified by lymphoscintigraphy was 1.36 (range 1-5) and mean number of SLNs removed at surgery was 1.55 (range 1-5), with an identification rate of 100%. The mean number of hot spots identified by lymphoscintigraphy was similar in patients who underwent single or double injections (1.36 and 1.35, respectively). In 21 of 42 patients the SLN was positive, and in seven of these 21 patients the SLN was the only positive node. After a median follow-up of 24 months no overt axillary metastases occurred in patients with negative SLN. Conclusions: The number of SLNs is not dependent on the number and site of injections. SLNB is our standard procedure for nodal staging in patients with multicentric breast cancer and a clinically negative axilla.

AB - Aim: To present our experience with sentinel lymph node biopsy (SLNB) performed in patients with multicentric breast cancer. Methods: Between May 2001 and May 2004, 42 patients with multicentric breast cancer and a clinically negative axilla underwent lymphatic mapping either by a single subareolar (n=25) or a double peritumoral/subdermal injection (n=17) of 99Tc-HSA nanocolloids. The sentinel lymph node (SLN) was evaluated by intraoperative frozen section and axillary dissection was performed only in case of positive SLN. Results: Mean age was 49 years (range 25-78). Mean number of SLNs identified by lymphoscintigraphy was 1.36 (range 1-5) and mean number of SLNs removed at surgery was 1.55 (range 1-5), with an identification rate of 100%. The mean number of hot spots identified by lymphoscintigraphy was similar in patients who underwent single or double injections (1.36 and 1.35, respectively). In 21 of 42 patients the SLN was positive, and in seven of these 21 patients the SLN was the only positive node. After a median follow-up of 24 months no overt axillary metastases occurred in patients with negative SLN. Conclusions: The number of SLNs is not dependent on the number and site of injections. SLNB is our standard procedure for nodal staging in patients with multicentric breast cancer and a clinically negative axilla.

KW - Breast cancer

KW - Multicentric

KW - Sentinel node

UR - http://www.scopus.com/inward/record.url?scp=33746880308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746880308&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2006.02.018

DO - 10.1016/j.ejso.2006.02.018

M3 - Article

C2 - 16595168

AN - SCOPUS:33746880308

VL - 32

SP - 507

EP - 510

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 5

ER -